DaVita Change in Accounts Receivable 2010-2025 | DVA
DaVita annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- DaVita change in accounts receivable for the quarter ending June 30, 2025 was $-0.288B, a 49.38% increase year-over-year.
- DaVita change in accounts receivable for the twelve months ending June 30, 2025 was $-0.649B, a 39.94% increase year-over-year.
- DaVita annual change in accounts receivable for 2024 was $-0.03B, a 117.27% decline from 2023.
- DaVita annual change in accounts receivable for 2023 was $0.172B, a 216.15% decline from 2022.
- DaVita annual change in accounts receivable for 2022 was $-0.148B, a 7.42% increase from 2021.
DaVita Annual Change in Accounts Receivable
(Millions of US $) |
| 2024 |
$-30 |
| 2023 |
$172 |
| 2022 |
$-148 |
| 2021 |
$-138 |
| 2020 |
$-21 |
| 2019 |
$-80 |
| 2018 |
$-81 |
| 2017 |
$-156 |
| 2016 |
$-152 |
| 2015 |
$-203 |
| 2014 |
$-41 |
| 2013 |
$-60 |
| 2012 |
$-48 |
| 2011 |
$-89 |
| 2010 |
$55 |
| 2009 |
$-32 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$10.036B |
$12.816B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
